Edgewise Therapeutics Reports Improvements in Heart Drug Trial

Edgewise Therapeutics Inc. (NASDAQ:EWTX) on Tuesday released topline results from the 12-week Part D cohort of its Phase 2 CIRRUS-HCM trial. Patients received doses ranging from 25 mg to 150 mg. EDG-7500 demonstrated clinically meaningful improvements in patients with both…

Money
Jun 16, 2026
Bitcoin ETFs Shed All Inflows Made After Trump 2024 Election Win

Bitcoin (CRYPTO: BTC) ETF net assets fell to $77.58 billion on Tuesday, the lowest level since the last presidential election, notwithstanding the most crypto-friendly regulatory environment in US history. Every Post-Election Gain Is Gone Despite The Best Regulatory Climate Ever…

Money
Jun 10, 2026
Ingredion To Acquire Tate & Lyle for $5 Billion In All-Cash Deal

On Monday, Ingredion Inc. (NYSE:INGR) announced a recommended all-cash acquisition of Tate & Lyle PLC valued at about 3.7 billion pounds ($5 billion), expanding its specialty ingredients business. The deal broadens Ingredion’s portfolio in texturants, sugar reduction, and fortification while…

Money
Jun 08, 2026
Full Transcript: Quanex Building Prods Q2 2026 Earnings Call

On Friday, Quanex Building Prods (NYSE:NX) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive financial data and transcripts, visit https://www.benzinga.com/apis/. View the webcast at https://edge.media-server.com/mmc/p/z3ha9hb3/…

Money
Jun 05, 2026